PAREXEL launches marketing initiative to simplify journey from science to new treatments


As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company’s proven approach to help clients simplify the journey from science to new treatments.

Drug development today is a demanding and difficult process. Increasingly, pharmaceutical companies are under pressure to accelerate development and introduce innovative new medicines and treatments in an increasingly complex and competitive environment. To assist in these efforts, companies are seeking a partner that can help simplify and accelerate all aspects of product development.

“In today’s market, biopharmaceutical companies must effectively balance global requirements with regional and local issues, address clinical trial complexity and seek ways to make the drug development process more efficient,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “For more than 30 years, our mission has been to help the biopharmaceutical and medical device industries prevent and cure disease. While that mission hasn’t changed, the way we promote our mission is changing. PAREXEL’s new brand platform clearly defines how we can simplify drug development by applying our unique capabilities to the work we do. This will help clients better understand the full scope of our portfolio, and how individual offerings interrelate.”

Your Journey. Our Mission.â„¢

PAREXEL’s new brand promise, “Your Journey. Our Mission™ ,” represents the Company’s commitment to make each client’s journey its mission. The Company works to fulfill this commitment through its: